// changes done below on July 01 2024 // till here on July 01 2024

Immune Checkpoint Inhibitors: A New Hope for Cancer Patients

Published: September 2015

Roots Analysis has announced the addition of “Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025” report to its portfolio. The study provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of Immune Checkpoint Inhibitors (ICIs).

Rupali Verma, the principal analyst, said, “The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were pioneers in this segment. Yervoy was the only immunotherapeutic commercially available until other classes stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost. In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which are expected to gain traction in the future.”

Verma further stated, “The market is currently characterized by the presence of three marketed drugs and 34 drugs in clinical development.

  • BMS, with ten ICIs, is the leading player followed by other giants including AstraZeneca, Merck, Pfizer, Roche, GSK, Novartis and Amgen.
  • Several molecules are being tested in combination with other drug classes; Jan 2014-May 2015 saw over 40 such collaborations.”

Amongst other things, the report covers:

  • Current market outlook, along with key drivers and restraints, likely to influence future growth.
  • Detailed analysis of the active/planned clinical studies evaluating phase II/III/marketed ICIs.
  • Partnering activities which are likely to unfold as the market matures.
  • Investments and grants received by companies focused in this area.
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.

In addition to the initiatives taken by the bigger firms, the report covers many start-ups and small companies which have also emerged. Examples include

  • Agenus
  • Alligator Bioscience
  • Ambrx
  • AnaptysBio
  • arGEN-X
  • Bioceros
  • BioNovion
  • Cellerant Therapeutics
  • Checkpoint Therapeutics
  • Compugen
  • CureTech
  • Enumeral
  • Five Prime Therapeutics
  • Genmab
  • GITR
  • ImmuNext
  • IOmet Pharma
  • iTeos Therapeutics
  • Jounce Therapeutics
  • KAHR Medical
  • Multimeric Biotherapeutics
  • Nativis
  • Orega Biotech
  • Pelican Therapeutics
  • Pieris Pharmaceuticals
  • Prima BioMed
  • Redx Pharma
  • Tesaro
  • TG Therapeutics
  • Theravectys
  • ToleroTech

 For additional details, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors-market-2nd-edition-2015-2025/101.html or email sales@rootsanalysis.com


About Roots Analysis

Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at info@rootsanalysis.com


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry